Table 1.
Patient characteristics.
| Characteristics | All, N = 267 |
|---|---|
| Sex | |
| Female | 131 (49.1%) |
| Male | 136 (50.9%) |
| Age at time of second ASCT (years) | |
| Median (Q1; Q3) | 61.0 (55.0–64.0) |
| ISS score at diagnosis of MM | |
| I | 72 (27.0%) |
| II | 46 (17.2%) |
| III | 41 (15.4%) |
| Missing | 108 (40.4%) |
| Cytogenetic risk at diagnosis of MM | |
| Higha | 30 (11.2%) |
| Intermediate/low | 135 (50.6%) |
| Missing | 102 (38.2%) |
| Time without new treatment after first ASCT (months) | |
| Median (Q1; Q3) | 40.0 (28.5–58.0) |
| Number of prior line(s) of therapy before second ASCT | |
| 1 (i.e., second ASCT at first relapse) | 220 (82.4%) |
| >1 (i.e., second ASCT at second relapse or later) | 47 (17.6%) |
| Induction regimen prior to second ASCT | |
| IMiD & PI‐based | 134 (50.2%) |
| PI‐based | 60 (22.5%) |
| IMiD‐based | 46 (17.2%) |
| Anti‐CD38 mAb‐based | 10 (3.7%) |
| Conventional chemotherapy and others (including no treatment or radiotherapy alone) | 17 (6.4%) |
| Conditioning regimen of second ASCT | |
| Intensive (melphalan + busulfan or melphalan + TBI) | 33 (12.4%) |
| Standard (melphalan 200 mg/m²) | 183 (68.5%) |
| Reduce (melphalan 140 mg/m² or melphalan 100 mg/m²) | 51 (19.1%) |
| Consolidation therapy after second ASCT | |
| Yes | 128 (47.9%) |
| No | 139 (52.1%) |
| Maintenance therapy after second ASCT | |
| Yes | 107 (40.1%) |
| No | 160 (59.9%) |
Abbreviations: ASCT, autologous stem‐cell transplantation; IMiD, immunomodulatory drug; ISS, International Staging System; MM, multiple myeloma; mAb, monoclonal antibody; PI, proteasome inhibitor; TBI, total body irradiation.
a
t(4;14), t(14;16), t(14;20), del(17p), del(1p32) and 1q amplification.